Improved Completion Rates and Characterization of Drug Reactions with an Intensive Chagas Disease Treatment Program in Rural Bolivia

PLoS Neglected Tropical Diseases

Volumn 7, Issue 9, 2013, Pages

  Tornheim, Jeffrey A ^a   Lozano Beltran, Daniel F ^b   Gilman, Robert H ^c   Castellon, Mario ^b   Solano Mercado, Marco A ^b   Sullca, Walter ^d   Torrico, Faustino ^b   Bern, Caryn ^e  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSIDAD MAYOR DE SAN SIMÓN   (Bolivia)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d Hospital Dr Manuel Ascencio Villarroel de Punata   (Bolivia)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTIHISTAMINIC AGENT; BENZNIDAZOLE;

ADULT; AGE; AGEUSIA; ARTICLE; BOLIVIA; CHAGAS DISEASE; COMPARATIVE STUDY; DISEASE SEVERITY; DRUG SAFETY; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; GASTROINTESTINAL DISEASE; GENDER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NEUROLOGIC DISEASE; PATIENT ATTITUDE; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; SELF REPORT; SKIN DISEASE; STRUCTURED QUESTIONNAIRE; TREATMENT OUTCOME; TRYPANOSOMA CRUZI;

ADOLESCENT; ADULT; ANTIPROTOZOAL AGENTS; BOLIVIA; CHAGAS DISEASE; COHORT STUDIES; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; NITROIMIDAZOLES; PROSPECTIVE STUDIES; RURAL POPULATION; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884691200     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0002407     Document Type: Article

References (28)

1. World Health Organization (2010) First WHO Report on Neglected Tropical Diseases: Working to Overcome the Global Impact of Neglected Tropical Diseases. Geneva: WHO Press. 172 p.
2. Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, et al. (2007) Evaluation and treatment of Chagas disease in the United States: a systematic review. JAMA 298: 2171-2181.
3. Ministério DSB, (2005) [Brazilian Consensus on Chagas disease]. Rev Soc Bras Med Trop 38: 7-29.
4. Maguire JH, Hoff R, Sherlock I, Guimaraes AC, Sleigh AC, et al. (1987) Cardiac morbidity and mortality due to Chagas' disease: prospective electrocardiographic study of a Brazilian community. Circulation 75: 1140-1145.
5. Bern C, Montgomery SP, (2009) An estimate of the burden of Chagas disease in the United States. Clin Infect Dis 49: e52-4 Available: http://cid.oxfordjournals.org/content/49/5/e52.long. Accessed 15 August 2013.
6. Marin-Neto JA, Rassi A Jr, Morillo CA, Avezum A, Connolly SJ, et al. (2008) Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 156: 37-43.
7. Viotti R, Vigliano C, Lococo B, Bertocchi G, Petti M, et al. (2006) Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 144: 724-734.
8. Jackson Y, Alirol E, Getaz L, Wolff H, Combescure C, et al. (2010) Tolerance and safety of nifurtimox in patients with chronic Chagas disease. Clin Infect Dis 51: e69-e75 Available: http://cid.oxfordjournals.org/content/51/10/e69.long. Accessed 15 August 2013.
9. Hart JE, Jeon CY, Ivers LC, Behforouz HL, Caldas A, et al. (2010) Effect of directly observed therapy for highly active antiretroviral therapy on virologic, immunologic, and adherence outcomes: a meta-analysis and systematic review. J Acquir Immune Defic Syndr 54: 167-179.
10. Illanes Velarde D, Vallejo E, Rojas A, Nava J. (2007) Análisis de la Situación de Salud en el Departamento de Cochabamba 2005-2006. Cochabamba: SEDES Cochabamba.
11. Lázzari JO, Pereira M, Antunes CM, Guimarães A, Moncayo A, et al. (1998) Diagnostic electrocardiography in epidemiological studies of Chagas' disease: multicenter evaluation of a standardized method. Rev Panam Salud Publica 4: 317-330.
12. Instituto Nacional de Seguros de Salud (2005) Normas de Diagnóstico y Tratamiento Médico en Efermedades Tropicales. La Paz: Ministerio de Salud y Deportes.
13. Lee JY, Kusek JW, Greene PG, Bernhard S, Norris K, et al. (1996) Assessing medication adherence by pill count and electronic monitoring in the African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Am J Hypertens 9: 719-725.
14. Ministerio de Salud y Deportes, Programa Nacional de Chagas (2007) Protocolo - Manejo de las Reacciones Adversas por Tratamiento Etiológico de la Enfermedad de Chagas. La Paz: Ministerio de Salud y Deportes. 57 p.
15. Liu H, Golin CE, Miller LG, Hays RD, Beck CK, et al. (2001) A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med 134: 968-977.
16. Kikuchi K, Poudel KC, Muganda J, Majyambere A, Otsuka K, et al. (2012) High risk of ART non-adherence and delay of ART initiation among HIV positive double orphans in Kigali, Rwanda. PLoS One 7: e41998 Available: http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0041998. Accessed 15 August 2013.
17. Ngamvithayapong J, Uthaivoravit W, Yanai H, Akarasewi P, Sawanpanyalert P, (1997) Adherence to tuberculosis preventive therapy among HIV-infected persons in Chiang Rai, Thailand. AIDS 11: 107-112.
18. Campbell JI, Ruano AL, Samayoa B, Estrado Muy DL, Arathoon E, et al. (2010) Adherence to antiretroviral therapy in an urban, free-care HIV clinic in Guatemala City, Guatemala. J Int Assoc Physicians AIDS Care (Chic) 9: 390-395.
19. Winkler A, Teuscher AU, Mueller B, Diem P, (2002) Monitoring adherence to prescribed medication in type 2 diabetic patients treated with sulfonylureas. Swiss Med Wkly 132: 379-385.
20. Jasti S, Siega-Riz AM, Cogswell ME, Hartzema AG, (2006) Correction for errors in measuring adherence to prenatal multivitamin/mineral supplement use among low-income women. J Nutr 136: 479-483.
21. Namkoong K, Farren CK, O'Connor PG, O'Malley SS, (1999) Measurement of compliance with naltrexone in the treatment of alcohol dependence: research and clinical implications. J Clin Psychiatry 60: 449-453.
22. Pinazo MJ, Muñoz J, Posada E, López-Chejade P, Gállego M, et al. (2010) Tolerance of benznidazole in treatment of Chagas' disease in adults. Antimicrob Agents Chemother 54: 4896-4899.
23. Sosa-Estani S, Armenti A, Araujo G, Viotti R, Lococo B, et al. (2004) [Treatment of Chagas disease with benznidazole and thioctic acid]. Medicina (B Aires) 64: 1-6.
24. Pinazo MJ, Guerrero L, Posada E, Rodríguez E, Soy D, et al. (2013) Benznidazole-related adverse drug reactions and their relationship to serum drug concentrations in patients with chronic chagas disease. Antimicrob Agents Chemother 57: 390-395.
25. Altcheh J, Moscatelli G, Moroni S, Garcia-Bournissen F, Freilij H, (2011) Adverse events after the use of benznidazole in infants and children with Chagas disease. Pediatrics 127: e212-e218 Available: http://pediatrics.aappublications.org/content/127/1/e212.long. Accessed 15 August 2013.
26. Rassi A Jr, Rassi A, Little WC, Xavier SS, Rassi SG, et al. (2006) Development and validation of a risk score for predicting death in Chagas' heart disease. N Engl J Med 355: 799-808.
27. Viotti R, Vigliano C, Lococo B, Petti M, Bertocchi G, et al. (2006) Exercise stress testing as a predictor of progression of early chronic Chagas heart disease. Heart 92: 403-404.
28. Viotti RJ, Vigliano C, Laucella S, Lococo B, Petti M, et al. (2004) Value of echocardiography for diagnosis and prognosis of chronic Chagas disease cardiomyopathy without heart failure. Heart 90: 655-660.